Literature DB >> 9833772

Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression.

D Theodorescu1, K R Laderoute, J M Calaoagan, K M Guilding.   

Abstract

A significant portion of patients who present with non-muscle invasive "superficial" bladder cancer develop the muscle "invasive" life-threatening form of the disease during subsequent follow-up. In clinical studies, overexpression of the epidermal growth factor receptor (EGFR) and the p21 ras oncogene have been strongly associated with this phenotypic tumor transition. The marked difference in incidence of invasive bladder cancer in Asia compared to the United States has made us hypothesize that, among other factors, dietary influences have an impact on such tumor progression. A significantly higher dietary consumption of soy products exists in Asia and has led to the notion that the isoflavones present in this diet may contribute to a reduction in the number of invasive transitional cell bladder cancers. In this regard, we sought to determine the effect of genistein, a naturally occurring dietary protein tyrosine kinase (PTK) inhibitor, on the growth and motility of human bladder cancer cell lines with diverse EGFR and p21ras expression phenotypes and corresponding invasive behaviors. These effects were compared with those of tyrphostin, a pure synthetic EGFR inhibitor. Our results indicate that both genistein and tyrphostin are effective inhibitors of bladder cancer motility and growth, key factors in the development of muscle invasive disease. In addition, the growth and motility inhibitory effects of genistein and tyrphostin are observed preferentially in cells that overexpress the EGFR. Cells that have a mutated p21ras but do not overexpress the EGFR are less inhibited by these 2 compounds, suggesting that their effect is primarily directed at the EGFR signal transduction pathways proximal to the p21ras gene. Our results would seem to corroborate the notion that a high dietary intake of isoflavones is a likely explanation for the decreased incidence of invasive bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833772     DOI: 10.1002/(sici)1097-0215(19981209)78:6<775::aid-ijc16>3.0.co;2-g

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation.

Authors:  X Chen; H Zhou; Y B Liu; J F Wang; H Li; C Y Ung; L Y Han; Z W Cao; Y Z Chen
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

3.  A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Authors:  Edward Messing; Jason R Gee; Daniel R Saltzstein; KyungMann Kim; Anthony diSant'Agnese; Jill Kolesar; Linda Harris; Adrienne Faerber; Thomas Havighurst; Jay M Young; Mitchell Efros; Robert H Getzenberg; Marcia A Wheeler; Joseph Tangrea; Howard Parnes; Margaret House; J Erik Busby; Raymond Hohl; Howard Bailey
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-31

Review 4.  Tyrosine kinase inhibitors in preclinical development.

Authors:  M L Levitt; P P Koty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis.

Authors:  Ajita V Singh; Adrian A Franke; George L Blackburn; Jin-Rong Zhou
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

Review 6.  Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals.

Authors:  Onat Kadioglu; Jingming Cao; Mohamed E M Saeed; Henry Johannes Greten; Thomas Efferth
Journal:  Target Oncol       Date:  2014-11-21       Impact factor: 4.493

7.  Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells.

Authors:  Lara H El Touny; Partha P Banerjee
Journal:  Biochem Biophys Res Commun       Date:  2007-07-16       Impact factor: 3.575

8.  Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.

Authors:  Jill M Kolesar; Marcia Pomplun; Tom Havighurst; Jeanne Stublaski; Barbara Wollmer; KyungMann Kim; Joseph A Tangrea; Howard L Parnes; Margaret G House; Jason Gee; Edward Messing; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-03-17       Impact factor: 1.809

9.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

10.  H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells.

Authors:  C Li; R-H Teng; Y-C Tsai; H-S Ke; J-Y Huang; C-C Chen; Y-L Kao; C-C Kuo; W R Bell; B Shieh
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.